Smoking cessation products' broader efficacy claims to be discussed by FDA advisory cmte..
This article was originally published in The Tan Sheet
Executive Summary
SMOKING CESSATION PRODUCTS LABELED EFFICACY CLAIMS will be discussed by FDA's Drug Abuse Advisory Committee at a meeting scheduled for June 9 at the Holiday Inn in Bethesda, Md. The meeting is being held to continue a discussion that took place at the committee's Feb. 10 session regarding New Life Health Products' Quit brand of silver acetate lozenges ("The Tan Sheet" Feb. 17, p. 6).